Theodorus

Thomas LIENARD, CEO

"Theodorus helped Bone Therapeutics as a lead investor from its seed funding until its IPO. Its managers gave us a strong support during our various funding rounds."

François TORCHE, , CEO

"A strong corporate structure is a key asset to improve the scalability of the business. Theodorus helped us improve our governance and our decision-making process in order to focus on actions that create long term value and increase the chances of a successful EXIT."

Investment Portfolio

Exit

Medtech

Sector: Medtech; Employees: 4; Medical device company dedicated to the development of innovative devices for gastroenterologic interventions. It has been acquired by an industrial group in 2016.

Ongoing

Affiliated fund

Sector: Affiliated fund; Employees:; 5.4M€ closed fund investing in Life Sciences and Engineering spin-offs from Université Libre de Bruxelles (ULB), either in seed or early stages.

Ongoing

Affiliated fund

Sector: Affiliated fund; Employees:; 15 M€ venture capital fund dedicated to seed investment in Belgian digital companies. With a first investment in the form of convertible loans, Seeder Fund can invest up to 1 M€ in further rounds in the most promising projects.

Exit

Biotech

Sector: Biotech; Employees: 101; Bone cell therapy company offering a broad portfolio of innovative allogeneic cell therapy solutions in the field of orthopaedics and bone diseases. BONE THERAPEUTICS went public on Euronext in 2015 and raised 32 M€ (over-subscription 2.5x)

Exit

High tech

Sector: High tech; Employees: 40; Designs, develops and manufactures optical and metrology systems and sub-systems for space, industry and ophthalmology. It has been acquired through an MBO in 2008.

Exit

High tech

Sector: High tech; Employees: 15; Global leader in Advanced 2-Phase Cooling Solutions for electronic components in Data Centers, Transport and Energy markets.

Exit

Biotech

Sector: Biotech; Employees: 41; Clinical-stage drug discovery company that invents and develops small molecule drugs. It has been acquired by Astellas in 2017 for 800 M€ (publicly disclosed)

Exit

Incubator

Sector: Incubator; Employees: 2; Originally founded by the Université Libre de Bruxelles (ULB), Biopark brings together a unique ecosystem of scientific, clinical and business expertise with world class facilities to create a perfect environment for drug research and development.

Ongoing

Biotech

Sector: Biotech; Employees: 7; Research and development company specialized in attractive and natural traps to eradicate domestic and agricultural insects/mites.

Ongoing

Biotech

Sector: Biotech; Employees: 12; Expert company in genetic engineering and provides bioproduction services with a core business in plasmid DNA development and applications.

Exit

Biotech

Sector: Biotech; Employees: 112; Contract Manufacturing Organization offering bioprocess development and manufacturing services from the cell bank to the supply of clinical products. It has been acquired by Novasep in 2009.

Ongoing

Biotech

Sector: Biotech; Employees: 5; Laboratory specialized in the identification of asbestos fibres presents in bulk samples and air samples.

Exit

Biotech

Sector: Biotech; Employees: 130; Dynamic and global Contract Development and Manufacturing Organization for cell therapy companies. It has entered a share deal with Orgenesis in 2015.

Exit

High tech

Sector: High tech; Employees: 47; European leader in Space Thermal control systems based upon 2-Phase Systems with more than 30 years of in orbit heritage. It has been acquired by Airbus Defence and Space in 2017.

Investment Portfolio

Exit

High tech

Sector: High tech; Employees: 47; European leader in Space Thermal control systems based upon 2-Phase Systems with more than 30 years of in orbit heritage. It has been acquired by Airbus Defence and Space in 2017.

Exit

Biotech

Sector: Biotech; Employees: 130; Dynamic and global Contract Development and Manufacturing Organization for cell therapy companies. It has entered a share deal with Orgenesis in 2015.

Exit

Biotech

Sector: Biotech; Employees: 101; Bone cell therapy company offering a broad portfolio of innovative allogeneic cell therapy solutions in the field of orthopaedics and bone diseases. BONE THERAPEUTICS went public on Euronext in 2015 and raised 32 M€ (over-subscription 2.5x)

Exit

Medtech

Sector: Medtech; Employees: 11; Provides advanced microscopes dedicated to automated viable cell counting.

Exit

Biotech

Sector: Biotech; Employees:; Developed personalised diagnostic tests for breast cancer. Its operational development failed.

Liquidated

Biotech

Sector: Biotech; Employees: Developed genetically m;odified mice. Its commercial development failed.

Exit

High tech

Sector: High tech; Employees: 40; Designs, develops and manufactures optical and metrology systems and sub-systems for space, industry and ophthalmology. It has been acquired through an MBO in 2008.

Exit

Medtech

Sector: Medtech; Employees: 4; Medical device company dedicated to the development of innovative devices for gastroenterologic interventions. It has been acquired by an industrial group in 2016.

Exit

High tech

Sector: High tech; Employees: 15; Global leader in Advanced 2-Phase Cooling Solutions for electronic components in Data Centers, Transport and Energy markets.

Investment Portfolio

Exit

Biotech

Sector: Biotech; Employees: 41; Clinical-stage drug discovery company that invents and develops small molecule drugs. It has been acquired by Astellas in 2017 for 800 M€ (publicly disclosed)

Exit

Biotech

Sector: Biotech; Employees: 130; Dynamic and global Contract Development and Manufacturing Organization for cell therapy companies. It has entered a share deal with Orgenesis in 2015.

Exit

High tech

Sector: High tech; Employees: 15; Global leader in Advanced 2-Phase Cooling Solutions for electronic components in Data Centers, Transport and Energy markets.

Exit

Medtech

Sector: Medtech; Employees: 11; Provides advanced microscopes dedicated to automated viable cell counting.

Exit

Biotech

Sector: Biotech; Employees: 2; EPICS Therapeutics is a newly created company dedicated to develop novel therapeutic solutions for cancer, based on the highly innovative field of RNA epigenetics.

Ongoing

High Tech

Sector: Biotech; Employees: 101; Bone cell therapy company offering a broad portfolio of innovative allogeneic cell therapy solutions in the field of orthopaedics and bone diseases. BONE THERAPEUTICS went public on Euronext in 2015 and raised 32 M€ (over-subscription 2.5x)

Ongoing

High Tech

Sector: Medtech; Employees: 15; Supplies micro-chip liquid chromatography cartridges designed for complex biological samples analysis and compatible with all standard nano-LC equipment.

Ongoing

High Tech

Sector: High tech; Employees: 2; Offers Innovative surface coating solutions for high-end applications.

Ongoing

Medtech

Sector: Medtech; Employees: 2; Unique product to eradicate dust mites. It eliminates the allergens and reduces allergic symptoms already after a first use.

Ongoing

Biotech

Sector: Biotech Employees: 3 ChromaCure’s mission is to discover and develop first-in-class small molecule therapeutics for unmet needs in oncology.

Ongoing

High Tech

Sector: High tech; Employees: 7; IT company that designs, produces and implements software to visualize, quantify and optimize the operations of Production plants, Maintenance sites, Distribution centers or Warehouses.

Ongoing

Medtech

Sector: Medtech; Employees: 3; Develops a disruptive ABO POCT device aiming to improve drastically transfusion safety at bedside.

Ongoing

Fintech

Sector: Fintech; Employees: 14; A single platform for all your debt collection partners Benchmark them, reduce costs and improve your net recovery rate

Ongoing

Medtech

Sector: Medtech; Employees: 50; Offers a Risk-Based Monitoring software to improve data quality, increase operational efficiency and reduce regulatory submission risk, in clinical studies runned by pharma companies, CRO, CTO

Ongoing

Biotech

Sector: Biotech; Employees: 6; Vet biopharma developing products for the treatment of orthopedic (bone, joint, tendon/ligament) conditions in dogs and horses.

Liquidated

High tech

Sector: High tech; Employees:; Develops products and services for residential and business consumers to decrease their energy consumption drastically using advanced technology.

Liquidated

High tech

Sector: High tech; Employees:; Develops and runs Gustaf, an online marketplace for digital and interactive sheet music.

Liquidated

High tech

Sector: High tech; Employees:; Company providing networking as-a-service. Its commercial development failed.

Investment Portfolio

Ongoing

Biotech

Sector: Biotech; Employees: 10; Apaxen is a privately-held biotechnology company, which brings new treatment options to patients in a wide range of therapeutic indications related to chronic inflammation, with a primary focus in pulmonary arterial hypertension (PAH)

Ongoing

High tech

Sector: High-tech; Employees: 40; Classcraft helps educators motivate learners to reach their potential through sustainable, playful learning experiences that promote growth and human connection.

Ongoing

Biotech

Sector: Biotech; Employees:; Founded in August 2019 by the ULB entrepreneurial team and Theodorus, the company is based on more than 10 years of dedicated applied research on inhaled lung cancer treatment held in the laboratory of Pharmaceutics and Biopharmaceutics (LPB)

Ongoing

Medtech

Sector: Medtech; Employees: 10; Moonshot Health is creating a new model of healthcare that moves beyond episodic, office-based medicine to provide preventive, continuous, collaborative care through the use of digital biomarkers.

Ongoing

Medtech

Sector: Medtech; Employees: 200; Icentia is a combined medical devices and service company based in Canada. It aims at providing a line of innovative medical testing solutions for healthcare institutions.

Ongoing

Biotech

Sector: Biotech; Employees: 10; The mission of the company is to develop novel therapeutic approaches for solid cancers and inflammatory diseases. The main focus is presently on small molecules targeting selected G protein-coupled receptors.

Ongoing

Medtech

Sector: Medtech; Employees: 7; Kaspard offers a technological solution address the monitoring and management of falls of elderly people in nursing homes.